184 related articles for article (PubMed ID: 15781183)
1. Inhibitor-based validation of a homology model of the active-site of tripeptidyl peptidase II.
De Winter H; Breslin H; Miskowski T; Kavash R; Somers M
J Mol Graph Model; 2005 Apr; 23(5):409-18. PubMed ID: 15781183
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach to designing exopeptidase inhibitors.
Ganellin CR; Bishop PB; Bambal RB; Chan SM; Leblond B; Moore AN; Zhao L; Bourgeat P; Rose C; Vargas F; Schwartz JC
J Med Chem; 2005 Nov; 48(23):7333-42. PubMed ID: 16279793
[TBL] [Abstract][Full Text] [Related]
3. Development, evaluation and application of tripeptidyl-peptidase II sequence signatures.
Eriksson S; Gutiérrez OA; Bjerling P; Tomkinson B
Arch Biochem Biophys; 2009 Apr; 484(1):39-45. PubMed ID: 19467630
[TBL] [Abstract][Full Text] [Related]
4. Exploring the active site of tripeptidyl-peptidase II through studies of pH dependence of reaction kinetics.
Eklund S; Lindås AC; Hamnevik E; Widersten M; Tomkinson B
Biochim Biophys Acta; 2012 Apr; 1824(4):561-70. PubMed ID: 22266401
[TBL] [Abstract][Full Text] [Related]
5. Nucleotide sequence of cDNA covering the N-terminus of human tripeptidyl peptidase II.
Tomkinson B
Biomed Biochim Acta; 1991; 50(4-6):727-9. PubMed ID: 1840501
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the endopeptidase activity of tripeptidyl-peptidase II.
Eklund S; Dogan J; Jemth P; Kalbacher H; Tomkinson B
Biochem Biophys Res Commun; 2012 Aug; 424(3):503-7. PubMed ID: 22771804
[TBL] [Abstract][Full Text] [Related]
7. Association and dissociation of the tripeptidyl-peptidase II complex as a way of regulating the enzyme activity.
Tomkinson B
Arch Biochem Biophys; 2000 Apr; 376(2):275-80. PubMed ID: 10775413
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design of inhibitors of NS3 serine protease of hepatitis C virus.
Frecer V; Kabelác M; De Nardi P; Pricl S; Miertus S
J Mol Graph Model; 2004 Jan; 22(3):209-20. PubMed ID: 14629979
[TBL] [Abstract][Full Text] [Related]
9. Characterization and inhibition of a cholecystokinin-inactivating serine peptidase.
Rose C; Vargas F; Facchinetti P; Bourgeat P; Bambal RB; Bishop PB; Chan SM; Moore AN; Ganellin CR; Schwartz JC
Nature; 1996 Apr; 380(6573):403-9. PubMed ID: 8602240
[TBL] [Abstract][Full Text] [Related]
10. Rat tripeptidyl peptidase I: molecular cloning, functional expression, tissue localization and enzymatic characterization.
Du PG; Kato S; Li YH; Maeda T; Yamane T; Yamamoto S; Fujiwara M; Yamamoto Y; Nishi K; Ohkubo I
Biol Chem; 2001 Dec; 382(12):1715-25. PubMed ID: 11843185
[TBL] [Abstract][Full Text] [Related]
11. Crystal structure and mechanism of tripeptidyl activity of prolyl tripeptidyl aminopeptidase from Porphyromonas gingivalis.
Ito K; Nakajima Y; Xu Y; Yamada N; Onohara Y; Ito T; Matsubara F; Kabashima T; Nakayama K; Yoshimoto T
J Mol Biol; 2006 Sep; 362(2):228-40. PubMed ID: 16914159
[TBL] [Abstract][Full Text] [Related]
12. Structural insights into the non-additivity effects in the sequence-to-reactivity algorithm for serine peptidases and their inhibitors.
Lee TW; Qasim MA; Laskowski M; James MN
J Mol Biol; 2007 Mar; 367(2):527-46. PubMed ID: 17266986
[TBL] [Abstract][Full Text] [Related]
13. Identification of the catalytic triad in tripeptidyl-peptidase II through site-directed mutagenesis.
Hilbi H; Jozsa E; Tomkinson B
Biochim Biophys Acta; 2002 Dec; 1601(2):149-54. PubMed ID: 12445476
[TBL] [Abstract][Full Text] [Related]
14. Ser475, Glu272, Asp276, Asp327, and Asp360 are involved in catalytic activity of human tripeptidyl-peptidase I.
Walus M; Kida E; Wisniewski KE; Golabek AA
FEBS Lett; 2005 Feb; 579(6):1383-8. PubMed ID: 15733845
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of tripeptidyl peptidase II. 2. Generation of the first novel lead inhibitor of cholecystokinin-8-inactivating peptidase: a strategy for the design of peptidase inhibitors.
Ganellin CR; Bishop PB; Bambal RB; Chan SM; Law JK; Marabout B; Luthra PM; Moore AN; Peschard O; Bourgeat P; Rose C; Vargas F; Schwartz JC
J Med Chem; 2000 Feb; 43(4):664-74. PubMed ID: 10691692
[TBL] [Abstract][Full Text] [Related]
16. Lysosomal degradation of cholecystokinin-(29-33)-amide in mouse brain is dependent on tripeptidyl peptidase-I: implications for the degradation and storage of peptides in classical late-infantile neuronal ceroid lipofuscinosis.
Bernardini F; Warburton MJ
Biochem J; 2002 Sep; 366(Pt 2):521-9. PubMed ID: 12038963
[TBL] [Abstract][Full Text] [Related]
17. Tripeptidyl-peptidase II: a multi-purpose peptidase.
Tomkinson B; Lindås AC
Int J Biochem Cell Biol; 2005 Oct; 37(10):1933-7. PubMed ID: 16125107
[TBL] [Abstract][Full Text] [Related]
18. Role of tripeptidyl peptidase II in MHC class I antigen processing - the end of controversies?
Endert Pv
Eur J Immunol; 2008 Mar; 38(3):609-13. PubMed ID: 18286570
[TBL] [Abstract][Full Text] [Related]
19. Structure modeling, ligand binding, and binding affinity calculation (LR-MM-PBSA) of human heparanase for inhibition and drug design.
Zhou Z; Bates M; Madura JD
Proteins; 2006 Nov; 65(3):580-92. PubMed ID: 16972282
[TBL] [Abstract][Full Text] [Related]
20. The insert within the catalytic domain of tripeptidyl-peptidase II is important for the formation of the active complex.
Tomkinson B; Ní Laoi B; Wellington K
Eur J Biochem; 2002 Mar; 269(5):1438-43. PubMed ID: 11874458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
